Erin M Kim1, Cara Randall2, Renee Betancourt2, Staci Keene2, Amy Lilly2, Mark Fowler2, Evan S Dellon1,3, Hans H Herfarth1,4. 1. Multidisciplinary Center for Inflammatory Bowel Disease, Chapel Hill, NC, USA. 2. Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Center for Esophageal Diseases and Swallowing, Chapel Hill, NC, USA. 4. Division of Gastroenterology and Hepatology, Chapel Hill, NC, USA.
Abstract
BACKGROUND: Peripheral and mucosal eosinophilia may be associated with more aggressive disease in inflammatory bowel disease (IBD) patients. Vedolizumab blocks T lymphocytes, eosinophil adhesion, and extravasation in the gastrointestinal tract. It is not known if mucosal eosinophilia is a predictor for the therapeutic efficacy of vedolizumab. METHODS: This was a retrospective cohort study of IBD patients with ileal or colonic biopsies who were off steroids before starting vedolizumab. Biopsies were rereviewed by pathologists, and mean eosinophil density was quantified. Patient characteristics and steroid-free clinical response 6 months after beginning vedolizumab were determined. Features were compared between nonresponders and responders, and multivariable logistic regression was performed to identify predictors of clinical response. RESULTS: Of 251 IBD patients starting vedolizumab therapy, 65 patients (48% Crohn's disease, 52% ulcerative colitis) met inclusion criteria. All IBD patients not responding to vedolizumab were more likely to have a higher baseline mean eosinophil count (340 ± 156 vs 236 ± 124; P = 0.004), be previously exposed to an anti-TNF (96% vs 56%; P = 0.001), and be male (58% vs 28%; P = 0.02). Mean eosinophil counts were significantly increased in colonic biopsies in UC nonresponders (438 ± 149 vs 299 ± 145; P = 0.01). A similar trend was seen in CD nonresponders. On multivariable analysis, colonic eosinophil density and prior anti-TNF exposure-and the combination of both-were independent predictors of response. CONCLUSION: In ulcerative colitis, colonic eosinophilia and prior anti-TNF exposure were independent predictors of 6-month clinical nonresponse to vedolizumab. Mucosal eosinophil density as a novel biomarker should be explored in larger patient cohorts.Aside from the previous anti-TNF exposure, eosinophil density in the colon of patients with UC is a negative predictor for a steroid-free long-term response to vedolizumab. The degree colonic eosinophilia may be a novel biomarker that should be further explored.
BACKGROUND: Peripheral and mucosal eosinophilia may be associated with more aggressive disease in inflammatory bowel disease (IBD) patients. Vedolizumab blocks T lymphocytes, eosinophil adhesion, and extravasation in the gastrointestinal tract. It is not known if mucosal eosinophilia is a predictor for the therapeutic efficacy of vedolizumab. METHODS: This was a retrospective cohort study of IBDpatients with ileal or colonic biopsies who were off steroids before starting vedolizumab. Biopsies were rereviewed by pathologists, and mean eosinophil density was quantified. Patient characteristics and steroid-free clinical response 6 months after beginning vedolizumab were determined. Features were compared between nonresponders and responders, and multivariable logistic regression was performed to identify predictors of clinical response. RESULTS: Of 251 IBDpatients starting vedolizumab therapy, 65 patients (48% Crohn's disease, 52% ulcerative colitis) met inclusion criteria. All IBDpatients not responding to vedolizumab were more likely to have a higher baseline mean eosinophil count (340 ± 156 vs 236 ± 124; P = 0.004), be previously exposed to an anti-TNF (96% vs 56%; P = 0.001), and be male (58% vs 28%; P = 0.02). Mean eosinophil counts were significantly increased in colonic biopsies in UC nonresponders (438 ± 149 vs 299 ± 145; P = 0.01). A similar trend was seen in CD nonresponders. On multivariable analysis, colonic eosinophil density and prior anti-TNF exposure-and the combination of both-were independent predictors of response. CONCLUSION: In ulcerative colitis, colonic eosinophilia and prior anti-TNF exposure were independent predictors of 6-month clinical nonresponse to vedolizumab. Mucosal eosinophil density as a novel biomarker should be explored in larger patient cohorts.Aside from the previous anti-TNF exposure, eosinophil density in the colon of patients with UC is a negative predictor for a steroid-free long-term response to vedolizumab. The degree colonic eosinophilia may be a novel biomarker that should be further explored.
Authors: N Plevris; C S Chuah; R M Allen; I D Arnott; P N Brennan; S Chaudhary; A M D Churchhouse; S Din; E Donoghue; D R Gaya; M Groome; H M Jafferbhoy; P W Jenkinson; W L Lam; M Lyons; J C Macdonald; M MacMaster; C Mowat; G D Naismith; L F Potts; E Saffouri; J P Seenan; A Sengupta; P Shasi; D I Sutherland; J A Todd; J Veryan; A J M Watson; D A Watts; G R Jones; C W Lees Journal: J Crohns Colitis Date: 2019-09-19 Impact factor: 9.071
Authors: Bharati Kochar; Edward L Barnes; Millie D Long; Kelly C Cushing; Joseph Galanko; Christopher F Martin; Laura E Raffals; Robert S Sandler Journal: Am J Gastroenterol Date: 2017-11-14 Impact factor: 10.864
Authors: Bruce E Sands; William J Sandborn; Gert Van Assche; Milan Lukas; Jing Xu; Alexandra James; Brihad Abhyankar; Karen Lasch Journal: Inflamm Bowel Dis Date: 2017-01 Impact factor: 5.325
Authors: Joanne C Masterson; Eóin N McNamee; Sophie A Fillon; Lindsay Hosford; Rachel Harris; Shahan D Fernando; Paul Jedlicka; Ryo Iwamoto; Elizabeth Jacobsen; Cheryl Protheroe; Holger K Eltzschig; Sean P Colgan; Makoto Arita; James J Lee; Glenn T Furuta Journal: Gut Date: 2014-09-10 Impact factor: 23.059
Authors: Christopher Ma; Rocio Sedano; Ahmed Almradi; Niels Vande Casteele; Claire E Parker; Leonardo Guizzetti; David F Schaeffer; Robert H Riddell; Reetesh K Pai; Robert Battat; Bruce E Sands; Christophe Rosty; Marla C Dubinsky; Florian Rieder; Noam Harpaz; Maria T Abreu; Robert V Bryant; Gregory Y Lauwers; Richard Kirsch; Mark A Valasek; Eileen Crowley; William J Sandborn; Brian G Feagan; Rish K Pai; Vipul Jairath Journal: Gastroenterology Date: 2021-02-19 Impact factor: 22.682
Authors: Patrizio Scarozza; Irene Marafini; Federica Laudisi; Edoardo Troncone; Heike Schmitt; Marco Vincenzo Lenti; Stefania Costa; Irene Rocchetti; Elena De Cristofaro; Silvia Salvatori; Ludovica Frezzati; Antonio Di Sabatino; Raja Atreya; Markus F Neurath; Emma Calabrese; Giovanni Monteleone Journal: J Clin Med Date: 2020-02-01 Impact factor: 4.241
Authors: Ruben Y Gabriëls; Arno R Bourgonje; Julius Z H von Martels; Tjasso Blokzijl; Rinse K Weersma; Kevin Galinsky; Julius Juarez; Klaas Nico Faber; Gursah Kats-Ugurlu; Gerard Dijkstra Journal: J Clin Med Date: 2022-07-16 Impact factor: 4.964